COMPARE · Data as of August 24, 2026
AZN vs ZTS
Verdict: Side-by-side breakdown using the Bull Rankings model. AZN scored 74.5, ZTS scored 57.1 — AZN leads.
Compare another set
Different reporting periods. ZTS's fundamentals are as of June 2026, but AZN's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
AZN
AstraZeneca PLC
74.5
$166.71 · $258.5B
fundamentals as of
Score gap
17.4
AZN leads
ZTS
Zoetis Inc.
57.1
$77.17 · $31.9B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestZTS12.6x
- Fastest growthAZN+8.6%
- Strongest balance sheetAZN0.64
- Highest qualityZTS85 / 100
- Largest discount to fair valueZTS-32%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
AZN
stronger →← stronger
ZTS
78
Qualityreturns · margins · balance sheet
85
78
Growthrevenue & earnings expansion
43
68
Valuevaluation vs sector peers
51
AZN is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
AZN
ZTS
$11.8bA-
FCF
$2.3bB
+8.6%B
Rev
+1.5%C
0.64C+
D/E
2.94D
24.9xB
P/E
12.6xA
1.43B
PEG
6.97D
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
AZN
ZTS
20% above
Price vs fair valuelower is cheaper
32% below
~13%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-4%/yr
-27%
1-yr DCF upside
+40%
-17%
5-yr DCF upside
+47%
+0%
10-yr DCF upside
+57%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AZN
Why this score
- Raising its dividend
ZTS
Why this score
- Buying back stock
- Raising its dividend
The companies
AZNAstraZeneca PLC
Why now
Drug Manufacturers - General · market cap $258.5b. Down 22% from 52-week high of $212.71 — deep drawdown territory. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $213.99 (implying +28% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ZTSZoetis Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $31.9b. Down 51% from 52-week high of $156.49 — deep drawdown territory. 16 sell-side analysts rate this a Buy with a mean 1-yr target of $100.63 (implying +30% upside).
Moat
Net margin 27% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 83% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.94 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 51% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where AZN and ZTS diverge
On the headline score the gap is 17.4 points in favor of AZN. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- GrowthAZN 78.5 · ZTS 43.1AZN +35.4
- ValueAZN 67.5 · ZTS 50.7AZN +16.8
- QualityAZN 78.1 · ZTS 85.0ZTS +6.9
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.